A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Due to the low number of patients recruited and the slow enrollment pace of patients, on 18 March 2022, the sponsor decided to terminate the BOSTON-4 safety and tolerability trial ahead of time.

Conditions

Bronchiolitis Obliterans Syndrome (BOS)
GVHD, Chronic
Stem Cell Transplant Complications

Interventions

DRUG: Liposomal Cyclosporine A
DRUG: Liposomal Placebo

Sponsor

Zambon SpA